Adjuvant engineering for cancer immunotherapy: Development of a synthetic TLR2 ligand with increased cell adhesion

Cancer Science

Volumn 101, Issue 7, 2010, Pages 1596-1603

  Akazawa, Takashi ^a   Inoue, Norimitsu ^a   Shime, Hiroaki ^a,b   Kodama, Ken ^a   Matsumoto, Misako ^a,b   Seya, Tsukasa ^a,b  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(2,3 BISPALMITOYLOXYPROPYL)CYS RGDS; BCG VACCINE; CELL WALL SKELETON; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTEGRIN; LIPOPEPTIDE; MACROPHAGE ACTIVATING LIPOPEPTIDE 2; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; C57BL 6 MOUSE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER TRANSPLANTATION; CELL ADHESION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTER; IN VITRO STUDY; INCUBATION TIME; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; SYNTHESIS; T LYMPHOCYTE ACTIVATION; TUMOR VOLUME;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; BCG VACCINE; CELL ADHESION; DENDRITIC CELLS; IMMUNOTHERAPY; LIGANDS; LIPOPEPTIDES; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; OLIGOPEPTIDES; TISSUE ENGINEERING; TISSUE THERAPY; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 2;

EID: 77954641956     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01583.x     Document Type: Article

References (48)

1. Seya T, Akazawa T, Tsujita T, Matsumoto M. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based Complement Alternat Med 2006, 3(1):31-8.
2. Akazawa T, Ebihara T, Okuno M. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci U S A 2007, 104(1):252-7.
3. Okamoto M, Oshikawa T, Tano T. Involvement of Toll-like receptor 4 signaling in interferon-g production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst 2003, 95(4):316-26.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10(9):909-15.
5. Celis E. Toll-like receptor ligands energize peptide vaccines through multiple paths. Cancer Res 2007, 67(17):7945-7.
6. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13(5):552-9.
7. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 2003, 23(6a):4369-76.
8. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
9. Miconnet I, Coste I, Beermann F. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction. J Immunol 2001, 166(7):4612-19.
10. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-95.
11. Kaisho T, Akira S. Toll-like receptors as adjuvant receptors. Biochim Biophys Acta 2002, 1589(1):1-13.
12. Hemmi H, Takeuchi O, Kawai T. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813):740-5.
13. Azuma I, Ribi EE, Meyer TJ, Zbar B. Biologically active components from mycobacterial cell walls: I Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst 1974, 52:95-101.
14. Hayashi A, Doi O, Azuma I, Toyoshima K. Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patients. Proc Jpn Acad 1998, 74:50-5. Ser. B
15. Uehori J, Fukase K, Akazawa T. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: monoacylated MDP confers TLR2/TLR4 activation. J Immunol 2005, 174(11):7096-103.
16. Tsuji S, Matsumoto M, Takeuchi O. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun 2000, 68:6883-90.
17. Uehori J, Matsumoto M, Tsuji S. Simultaneous blocking of human Toll-like receptor 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin (BCG)-peptidoglycan (PGN). Infect Immun 2003, 71:4238-49.
18. Akazawa T, Masuda H, Saeki Y. Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice. Cancer Res 2004, 64(2):757-64.
19. Kodama K, Higashiyama M, Takami K. Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: a case-control study. Surg Today 2009, 39(3):194-200.
20. Begum NA, Ishii K, Kurita-Taniguchi M. Mycobacterium bovis BCG cell wall-specific differentially expressed genes identified by differential display and cDNA subtraction in human macrophages. Infect Immun 2004, 72(2):937-48.
21. Matsumoto M, Seya T, Kikkawa S. Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int Immunopharmacol 2001, 1(8):1559-69.
22. Oppmann B, Lesley R, Blom B. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13(5):715-25.
23. Zou JP, Yamamoto N, Fujii T. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-g production by anti-tumor T cells. Int Immunol 1995, 7(7):1135-45.
24. Langowski JL, Zhang X, Wu L. IL-23 promotes tumour incidence and growth. Nature 2006, 442(7101):461-5.
25. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004, 21(4):467-76.
26. Shime H, Yabu M, Akazawa T. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol 2008, 180(11):7175-83.
27. Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J Immunol 2007, 178(12):7571-80.
28. Jackson DC, Lau YF, Le T. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004, 101(43):15440-5.
29. Schneider C, Schmidt T, Ziske C. Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model. Gut 2004, 53(3):355-61.
30. Murata M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci 2008, 99(7):1435-40.
31. Mühlradt PF, Kiess M, Meyer H, Süssmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997, 185(11):1951-8.
32. Okusawa T, Fujita M, Nakamura J. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun 2004, 72(3):1657-65.
33. Omueti KO, Beyer JM, Johnson CM, Lyle EA, Tapping RI. Domain exchange between human toll-like receptors 1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem 2005, 280(44):36616-25.
34. Voss S, Ulmer AJ, Jung G, Wiesmüller KH, Brock R. The activity of lipopeptide TLR2 agonists critically depends on the presence of solubilizers. Eur J Immunol 2007, 37(12):3489-98.
35. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 1997, 186:665-72.
36. Harui A, Roth MD, Vira D, Sanghvi M, Mizuguchi H, Basak SK. Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of aV-b3 integrins. J Leukoc Biol 2006, 79(6):1271-8.
37. Okada N, Masunaga Y, Okada Y. Gene transduction efficiency and maturation status in mouse bone marrow-derived dendritic cells infected with conventional or RGD fiber-mutant adenovirus vectors. Cancer Gene Ther 2003, 10(5):421-31.
38. Kaisho T, Takeuchi O, Kawai T, Hoshino K, Akira S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol 2001, 166(9):5688-94.
39. Helmich BK, Dutton RW. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and Homing properties of Tc1 and Tc2 effectors. J Immunol 2001, 166:6500-8.
40. Akazawa T, Shingai M, Sasai M. Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors. FEBS Lett 2007, 581(18):3334-40.
41. Matsumoto M, Nishiguchi M, Kikkawa S, Nishimura H, Nagasawa S, Seya T. Structural and functional properties of complement-activating protein M161Ag, a Mycoplasma fermentans gene product that induces cytokine production by human monocytes. J Biol Chem 1998, 273:12407-14.
42. Nishiguchi M, Matsumoto M, Takao T. Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions. J Immunol 2001, 166:2610-16.
43. Hida T, Hayashi K, Yukishige K, Tanida S, Kawamura N, Harada S. Synthesis and biological activities of TAN-1511 Analogues. J Antibiot 1995, 48(7):589-603.
44. Reutter F, Jung G, Baier W, Treyer B, Bessler WG, Wiesmüller KH. Immunostimulants and Toll-like receptor ligands obtained by screening combinatorial lipopeptide collections. J Pept Res 2005, 65(3):375-83.
45. Gobin SJ, Peijnenburg A, Keijsers V, van den Elsen PJ. Site a is crucial for two routes of IFN g-induced MHC class I transactivation: the ISRE-mediated route and a novel pathway involving CIITA. Immunity 1997, 6(5):601-11.
46. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002, 86(5):788-95.
47. Janssen ML, Oyen WJ, Dijkgraaf I. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. Cancer Res 2002, 62(21):6146-51.
48. Seya T, Matsumoto M, Tsuji S, Begum NA, Azuma I, Toyoshima K. Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag. Microbes Infect 2002, 4(9):955-61.